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Background: Matrix metalloproteinase-9 (MMP-9) has been shown to be induced by cytokines including TNF-α and
may contribute to bone inflammatory diseases. However, the mechanisms underlying MMP-9 expression induced
by TNF-α in MC3T3-E1 cells remain unclear.
Results: We applied gelatin zymography, Western blot, RT-PCR, real-time PCR, selective pharmacological inhibitors
of transcription (actinomycin D, Act.D), translation (cycloheximide, CHI), c-Src (PP1), MEK1/2 (U0126), p38 MAPK
(SB202190), JNK1/2 (SP600125), and NF-κB (Bay11-7082), respective siRNAs transfection, promoter assay, immuno-
fluorescence staining, and ELISA to investigate the MMP-9 expression and soluble ICAM-1 (sICAM-1) release induced
by TNF-α in MC3T3-E1 cells. Here we demonstrated that TNF-α-induced MMP-9 expression was attenuated by Act.D,
CHI, PP1, U0126, SB202190, SP600125, and Bay11-7082, and by the transfection with siRNAs for ERK2, p38 MAPK,
and JNK2. TNF-α-stimulated TNFR1, TRAF2, and c-Src complex formation was revealed by immunoprecipitation and
Western blot. Furthermore, TNF-α-stimulated NF-κB phosphorylation and translocation were blocked by Bay11-7082,
but not by PP1, U0126, SB202190, or SP600125. TNF-α time-dependently induced MMP-9 promoter activity which
was also inhibited by PP1, U0126, SB202190, SP600125, or Bay11-7082. Up-regulation of MMP-9 was associated with
the release of sICAM-1 into the cultured medium, which was attenuated by the pretreatment with MMP-2/9i, an
MMP-9 inhibitor.
Conclusions: In this study, we demonstrated that TNF-α up-regulates MMP-9 expression via c-Src, MAPKs, and
NF-κB pathways. In addition, TNF-α-induced MMP-9 expression may contribute to the production of sICAM-1 by
MC3T3-E1 cells. The interplay between MMP-9 expression and sICAM-1 release may exert an important role in the
regulation of bone inflammatory diseases.
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Matrix metalloproteinases (MMPs) are a family of extra-
cellular matrix (ECM)-degrading enzymes and induced
by different stimuli including growth factors, cytokines,
and tumor promoters [1]. MMPs play important roles in
inflammation, tissue remodeling, angiogenesis, wound
healing, and tumor invasion [2]. Furthermore, MMPs
can also cleave other proteinases, latent growth factors,
cell surface receptors and cell-cell adhesion molecules
[3]. The important roles of MMPs have been demon-
strated in bone using various approaches for ossification,
remodeling, and destruction. Several literatures demon-
strate that MMP-2, MMP-9, MMP-13, and MMP-14
expressed in the skeleton appear to function in ossifica-
tion and remodeling [4,5]. Furthermore, MMP-2 and
MMP-9 can degrade a variety of collagens including
basement membrane (type IV collagen), denatured fibril-
lar type I collagen (gelatin), and type V collagen in
osteoarticular diseases [6]. Moreover, the MMP-9 ex-
pression is highly inducible and implicated in inflamma-
tory processes. The MMP-9 expression level has been
shown to be increased in synovial effusions of rheuma-
toid arthritis (RA) and inflammatory arthritis (IA) sam-
ples [7]. In addition, co-culture of osteoarthritis (OA)
subchondral bone osteoblasts with normal articular car-
tilage chondrocytes resulted in significantly increased
the expression of MMP-2 and MMP-9 [8]. These studies
have indicated that the expression of MMP-9 may be
up-regulated during bone inflammation.
Several proinflammatory mediators, including tumor
necrosis factor-α (TNF-α) have been reported to be as-
sociated with many bone functions such as resorption
and inflammation. The expression of MMPs has been
shown to be regulated by several extracellular stimuli
such as TNF-α and IL-1β in various cell types [9,10].
Numerous studies have reported that TNF-α-induced
the MMP-9 up-regulation is involved in osteoclasts dur-
ing differentiation and bone destruction [11,12]. More-
over, previous studies have demonstrated that TNF-α
induces the MMP-9 expression in osteoblasts and bone
marrow-derived osteoprogenitor cells [13,14]. TNF-α is
also elevated in the bone inflammatory patients and may
exert as a major mediator in bone inflammatory diseases
[15,16]. Therefore, the expression of MMP-9 induced by
TNF-α may be integrated to the signaling networks that
augment bone inflammation by degradation of ECM.
Moreover, the expression of MMP-9 appears to be
highly regulated through mitogen-activated protein ki-
nases (MAPKs) and NF-κB in various cell types [10,17].
Cytokines such as TNF-α are reported to activate all of
MAPKs including extracellular-regulated protein kinase
(ERK1/2), p38 MAPK, and c-Jun-N-terminal kinase
(JNK1/2) [18,19]. In cultured human chorionic tropho-
blast cells, TNF-α stimulates the MMP-9 secretionthrough the TNFR1 signaling to the MAPK pathway
[20]. However, the mechanisms underlying TNF-α-
stimulated MAPK activation associated with the MMP-9
gene expression in osteoblasts remain unclear. There-
fore, it is needed to determine whether activation of
these MAPK pathways by TNF-α is linked to the MMP-
9 expression in osteoblasts. In addition, it is of interest
that many of the genes regulated by these MAPK path-
ways are dependent on NF-κB for transcription [21] and
leading to the MMP-9 gene expression at the transcrip-
tional level [17]. In human vascular smooth muscle cells,
the transcription factors NF-κB and AP-1 involved in
the p42/p44 MAPK-mediated MMP-9 expression in re-
sponse to TNF-α have been investigated [22]. However,
the intracellular signaling mechanisms underlying the
MMP-9 expression induced by TNF-α in osteoblast-like
MC3T3-E1 cells are not completely characterized.
The adhesion molecule intercellular adhesion molecule-1
(ICAM-1), in addition to its membrane-associated form
(mICAM-1), also exists as a soluble form (sICAM-1). In
the bone microenvironment, osteoblasts play a crucial role
in regulating consecutive stages of bone resorption, which
include osteoclast recruitment through receptor activator
of NF-κB ligand (RANKL) and mICAM-1 [23–25]. In clin-
ical studies, therapy with TNF-α antagonists is able to
modulate RANKL in favor of bone formation in patients
with RA. Moreover, ICAM-1 belongs to the immunoglobu-
lin superfamily which mostly serves as a counter-receptor
for leukocyte integrin, lymphocyte function-associated anti-
gen (LFA-1). Kurachi et al. have demonstrated that the
interaction between LFA-1 and ICAM-1 influences the de-
velopment of osteoclasts [25]. sICAM-1 is capable of bind-
ing to LFA-1 molecules [26]. Therefore, the elevated levels
of sICAM-1 are thought to have immunomodulatory con-
sequences [27]. Soluble selectins and ICAM-1 modulate
neutrophil-endothelial adhesion and diapedesis in vitro
[28]. TNF-α stimulated mICAM-1 and sICAM-1 elevation
in human osteoblast-like cells isolated from OA patients
[29]. The levels of sICAM-1 were also found to be elevated
in RA. Furthermore, the therapeutic approaches have been
taken to induce anti-inflammatory effects by blocking the
ICAM-1 and TNF-α-dependent pathway with respective
neutralizing antibodies [30,31]. However, the effects of the
TNF-α-induced MMP-9 expression on sICAM-1 produc-
tion remain unknown.
In this study, the mechanisms underlying TNF-α-
induced MMP-9 expression and the effects of increased
MMP-9 on MC3T3-E1 cells were investigated. We
found that the activation of three MAPKs (i.e. ERK1/2,
p38 MAPK, and JNK1/2) and NF-κB is essential for the
induction of the MMP-9 gene expression in these cells.
Moreover, the induction and activation of MMP-9 are
important for sICAM-1 release from MC3T3-E1 cells.
These results provide new insights into the mechanisms
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Minimal essential medium-alpha (α-MEM), fetal bovine
serum (FBS), and TRIzol were purchased from Invitrogen
(Carlsbad, CA). Hybond C membrane and ECL Western
blotting detection system were from Amersham Biosci-
ences (Buckinghamshire, UK). Recombinant human TNF-α
and the anti-TNFR1 neutralizing antibody were from R&D
System (Minneapolis, MN). Luciferase assay kit was from
Promega (Madison, WI). Metafectene transfection reagent
was from Biontex Lab (GmbH, Planegg/Martinsried,
Germany). SMARTpool RNA duplexes corresponding to
Src, TRAF2, ERK2, p38 MAPK, JNK2, and scrambled #2
siRNA were from Dharmacon Research Inc (Lafayette,
CO). Anti-phospho-IKKα/β, anti-phospho-NF-κB p65
(Ser536), anti-phospho-c-Src, anti-phospho-ERK1/2, anti-
phospho-p38 MAPK, anti-phospho-JNK1/2, and anti-
phospho-IκB-α antibodies were from Cell Signaling (Danver,
MA). anti-NF-κB (p65), anti-lamin A, anti-TRAF2, anti-
TNFR1, anti-c-Src, anti-ERK2, anti-p38, anti-JNK2, anti-
IκB-α, and anti-sICAM-1 antibodies were from Santa
Cruz (Santa Cruz, CA). The anti-GAPDH antibody was
from Biogenesis (Boumemouth, UK). Actinomycin D
(Act.D), cycloheximide (CHI), PP1, U0126, SB202190,
SP600125, GM6001, MMP2/9 inhibitor, and Bay11-7082
were from Biomol (Plymouth Meeting, PA). Enzymes and
other chemicals were from Sigma (St. Louis, MO).
MC3T3-E1 osteoblastic cell culture
Murine osteoblastic cell line, MC3T3-E1, a homoge-
neous source of non-transformed cell, was a gift from
Dr. Hyun-Mo Ryoo (Department of Oral Biochemistry,
Kyungpook National University, Taegu, Korea) [32].
MC3T3-E1 cells were plated in α-MEM containing 10%
(v/v) FBS at 37°C in a humidified 5% CO2 atmosphere.
When the cultures reach confluence (4 days), cells were
treated with 0.05% (w/v) trypsin/0.53 mM EDTA for
5 min at 37°C. The cell suspension was diluted with α-
MEM containing 10% (v/v) FBS to a concentration of
2 × 105 cells/ml. The cell suspension was plated onto
(1 ml/well) 12-well culture plates and (10 ml/dish) 10-
cm culture dishes for the measurement of protein ex-
pression and mRNA accumulation, respectively. Culture
medium was changed after 24 h and then every 3 days.
Gelatin zymography
MC3T3-E1 cells were plated onto 12-well culture plates
and made quiescent at confluence by incubation in
serum-free α-MEM for 24 h. Growth-arrested cells wereincubated with TNF-α at 37°C for the indicated time in-
tervals. When inhibitors were used, they were added 1 h
prior to the application of TNF-α. The culture medium
was collected and centrifuged at 14000 rpm for 5 min at
4°C to remove cells and debris, then each sample was
mixed with equal amounts of (×2) non-reducible sample
buffer and electrophoresed on 10% SDS-PAGE contain-
ing 1 mg/ml gelatin as the protease substrate, as previ-
ously described [33].
Preparation of cell extracts and Western blot analysis
Growth-arrested MC3T3-E1 cells were incubated with
TNF-α at 37°C for the indicated time intervals. The cells
were washed, scraped, collected, lysed with ice-cold lysis
buffer, and centrifuged at 45,000 g at 4°C for 1 h to yield the
whole cell extract [34]. Samples were denatured, subjected
to SDS-PAGE using a 10% running gel, and transferred
to nitrocellulose membrane. Membranes were incubated
overnight at 4°C with the anti-TRAF2, anti-TNFR1, anti-c-
Src, anti-ERK2, anti-p38, anti-JNK2, anti-phospho-c-Src,
anti-phospho-ERK1/2, anti-phospho-p38 MAPK, anti-
phospho-JNK1/2, anti-phospho-c-Jun, anti-phospho-IKKα/
β, anti-phospho-NF-κB (p65), anti-NF-κB (p65), anti-lamin
A, anti-sICAM-1 or anti-GAPDH antibody used at a dilu-
tion of 1:2,000 in 5% (w/v) BSA in TTBS [(50 mM Tris–
HCl, 150 mM NaCl, 0.05% (w/v) Tween 20, pH 7.4)]. Mem-
branes were incubated with a 1:1500 dilution of anti-rabbit
or anti-mouse horseradish peroxidase antibody for 1 h. The
immunoreactive bands were detected by ECL reagents.
Total RNA extraction, RT-PCR and real-time PCR analysis
Total RNA was isolated from MC3T3-E1 cells treated
with TNF-α for the indicated time intervals with TRIzol
according to the protocol of the manufacturer. RNA
concentration was spectrophotometrically determined at
260 nm. First-strand cDNA synthesis was performed
with 2 μg of total RNA using random hexamers as
primers in a final volume of 20 μl (5 μg/μl random hex-
amers, 1 mM dNTPs, 2 units/μl RNasin, and 10 units/μl
Moloney murine leukemia virus reverse transcriptase).
The reaction was carried out at 37°C for 60 min. cDNAs
encoding β-actin and MMP-9 were amplified from 3 to
5 μl of the cDNA reaction mixture using specific gene
primers. Oligonucleotide primers for β-actin and MMP-
9 were follow as: β-actin (514 bp): 5′-GAACCCT
AAGGCCAACCGTG-3′ (sense), 5′-TGGCATAGAG
GTCTTTACGG-3′ (antisense); MMP-9 (458 bp): 5′-
TGTTCAGCAAGGGGCGTGTC-3′ (sense) 5′-AAA
CAGTCCAACAAGAAAGG-3′ (anti-sense). The ampli-
fication was performed in 35 cycles at 55°C, 1 min; 72°C,
1 min; 94°C, 1 min. After the last cycle, all samples were
incubated for an additional 5 min at 72°C. The expres-
sion of β-actin was used as an internal control for the
assay of a constitutively expressed gene.
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pression assay system, using primers and probe mixes for
MMP-9 and endogenous GAPDH control genes. PCRs
were performed using a 7500 Real-Time PCR System
(Applied Biosystems, Foster City, CA). The primers were:
5′-(TGATGCCATTGCTGATATCCA)-3′ (sense), 5′-(CG
GATCCTCAAAGGCTGAGT)-3′ (anti-sense) for MMP-
9; 5′-(AACTTTGGCATCGTGGAAGG)-3′ (sense), 5′-(G
TGGATGCAGGGATGATGTTC)-3′ (anti-sense) for
GAPDH. Relative gene expression was determined by
the ΔΔCt method, where Ct meant threshold cycle.
All experiments were performed in triplicate (n = 3).
Co-immunoprecipitation assay
Cell lysates containing 1 mg of protein were incubated
with 2 μg of anti-TNFR1 antibody at 4°C for 24 h, and
then 10 μl of 50% protein A-agarose beads was added
and mixed at 4°C for 24 h. The immunoprecipitates
were collected and washed thrice with a lysis buffer
without Triton X-100. 5X Laemmli buffer was added
and subjected to electrophoresis on 12% SDS-PAGE,
and then blotted using the anti-TRAF2, anti-c-Src or
anti-TNFR1 antibody.
Promoter activity assay
A 710-bp (−720 to −11) segment from the 5′-promoter
region of the MMP-9 gene was cloned as described [22].
Briefly, the 710-bp segment at the 5′-flanking region of
the human MMP-9 gene was amplified by PCR using
specific primers from the human MMP-9 gene (acces-
sion no. D10051): 5′-ACATTTGCCCGAGCTCCTG
AAG-3′ (forward/SacI) and 5′-AGGGGCTGCCAGA
AGCTTATGGT-3′ (reverse/HindIII). The pGL3-Basic
vector, containing a polyadenylation signal upstream
from the luciferase gene, was used to construct the ex-
pression vectors by subcloning PCR-amplified DNA of
the MMP-9 promoter into the SacI/HindIII site of this
vector. The PCR products (pGL3-WT-MMP9) were
confirmed by their sizes, as determined by electrophor-
esis, and by DNA sequencing. Additionally, the intro-
duction of a double-point mutation into NF-κB to
generate pGL3-mt-κB-MMP9 was performed, using the
following (forward) primer: mt-κB-MMP9: 5′-
CTGCGGAAGACAGGCCGTTGCCCCAGTGGAATTC
CC-3′ [35]. The mutants were generated using the Quick
Change Site-Directed Mutagenesis Kit (Stratagene, La
Jolla, CA). MMP-9-luc or κB-luc plasmid was transfected
into MC3T3-E1 cells. After incubation with TNF-α
(15 ng/ml), cells were collected and disrupted by sonic-
ation in a lysis buffer (25 mM Tris, pH 7.8, 2 mM EDTA,
1% Triton X-100, and 10% glycerol). After centrifugation,
aliquots of the supernatants were tested for luciferase ac-
tivity using the luciferase assay system. Firefly luciferase
activities were standardized for β-galactosidase activity.Transfection with small interference RNAs
MC3T3-E1 cells were plated at 1 × 106 cells/ml (1 ml/
well) in 12-well culture plates for 24 h, reaching about
80% confluence. Cells were replaced with 0.4 ml of α-
MEM containing 10% FBS. The DNA Metafectene
reagent complex was prepared according to the in-
structions of the manufacturer (Biontex, Martinsried/
Planegg, Germany). The amount of siRNA directed
against, ERK2 (accession no. NM_138957; Dharmacon),
JNK2 (accession no. NM_002752; Dharmacon), p38 (ac-
cession no. NM_139013; Dharmacon), c-Src (accession
no. NM_19829; Dharmacon), TRAF2 (accession no.
NM_021138; Invitrogen) or control siRNA was kept at
100 nM for each well. The DNA Metafectene complex
(0.1 ml) was added to each well and then incubated at
37°C for 24 h. The cells were washed twice with PBS and
maintained in α-MEM containing 1% FBS for 72 h before
treatment with TNF-α for the indicated time intervals.
NF-κB translocation
MC3T3-E1 cells were seeded in a 10-cm dish. After they
reached 90% confluence, cells were starved for 24 h in
serum-free α-MEM medium. After stimulation with
15 ng/ml TNF-α for various time intervals, and when in-
hibitors were used, they were added 1 h prior to the ap-
plication of TNF-α. As previously described [34], the
cells were washed once with ice-cold PBS, 200 μl of
homogenization buffer A (20 mM Tris–HCl, pH 8.0,
10 mM EGTA, 2 mM EDTA, 2 mM dithiothreitol, 1 mM
phenylmethylsulfonyl fluoride, 25 μg/ml aprotinin, 10 μg/
ml leupeptin) was added to each dish, and the cells were
scraped into a 1.5-ml Eppendorf vial. The suspension
was sonicated for 10 s at the output 4 with a sonicator
(Misonix Inc., Farmingdale, NY) and centrifuged at
8000 rpm at 4°C for 5 min. The pellet was collected as
the nuclear fraction. The pellet was resuspended in
300 μl of homogenization buffer B (1% Triton X-100 in
buffer A) and sonicated for 10 sec. The supernatant was
centrifuged at 15000 rpm at 4°C for 15 min. The super-
natant was collected as a cytosolic fraction and the pellet
as a membrane fraction. Protein concentration was deter-
mined by using BCA reagents. Samples (30 μg protein)
were denatured and subjected to SDS-PAGE using a 10%
(w/v) running gel. Proteins were transferred to a nitrocel-
lulose membrane and the membranes were successively
incubated at room temperature with 1% (w/v) BSA in
TTBS for 1 h. The translocation of NF-κB was identified
and quantified by Western blot using the anti-phospho-
IκB-α, IκB-α, and NF-κB (p65) antibodies. The immuno-
reactive bands were detected by ECL reagents.
Immunofluorescent staining
MC3T3-E1 cells were plated on 6-well culture plates
with coverslips. Cells were further cultured in serum-
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for various time intervals. When inhibitors were used,
they were added 1 h prior to the application of TNF-α.
After washing twice with ice-cold PBS, the cells were
fixed with 4% (w/v) paraformaldehyde in PBS for
30 min, and then permeabilized with 0.3% Triton X-100
in PBS for 15 min. The staining was performed by incu-
bating with 10% normal goat serum in PBS for 30 min
followed by incubating with the primary NF-κB (p65)
antibody (1:100 dilution) for 1 h in PBS with 1% BSA,
washing thrice with PBS, incubating for 1 h with fluores-
cein isothiocyanate (FITC)-conjugated anti-rabbit anti-
body (1:100 dilution) in PBS with 1% BSA, washing
thrice with PBS, and finally mounting with aqueous
mounting medium. The cell nucleus was stained by
DAPI. The images were observed under a fluorescence
microscope (Zeiss, Axiovert 200 M).
Measurement of sICAM-1 generation
sICAM-1 released into the culture media of MC3T3-E1
cells was collected and detected by using an ELISA kit
according to the manufacturer’s instructions (R&D
System, Minneapolis, MN).
Statistical analysis of data
Concentration-effect curves were fitted and estimated by
using the GraphPad Prism Program (GraphPad, San
Diego, CA). Data were expressed as mean ± S.E.M. and
analyzed by one-way ANOVA followed with Tukey’s
post-hoc test. P < 0.05 was considered significant.
Results
TNF-α induces MMP-9 expression in MC3T3-E1 cells
TNF-α has been shown to induce the expression of
MMP-9 in human osteoblasts, osteoprogenitors, and
mesenchymal stem cells [13,36]. To determine the effect
of TNF-α on MMP-9 expression, MC3T3-E1 cells were
incubated with various concentrations of TNF-α for the
indicated time intervals. The conditioned media were
collected to determine the MMP-9 expression activity by
gelatin zymography. As shown in Figure 1A, the condi-
tioned media from MC3T3-E1 cells displayed proteolytic
activity at 110 kDa, corresponding to the pro-form of
mouse MMP-9, and TNF-α induced proMMP-9 expres-
sion in a time- and concentration-dependent manner.
There was a significant increase within 16 h and a max-
imal increase was achieved by 36–48 h during the period
of observation. In contrast, TNF-α had no effect on
MMP-2 expression which served as an internal control.
To further examine whether the increase in MMP-9 ex-
pression induced by TNF-α results from an increase of
MMP-9 mRNA expression, MC3T3-E1 cells were incu-
bated with 15 ng/ml TNF-α for the indicated time inter-
vals. The levels of MMP-9 mRNA were determined byRT-PCR and real-time PCR. As shown in Figure 1B,
TNF-α time-dependently induced the expression of
MMP-9 mRNA, a significant increase within 4 h and
reached a peak by 6 h. These data suggested that TNF-α
induces MMP-9 expression via increasing mRNA and
protein levels in MC3T3-E1 cells. We further investi-
gated whether TNF-α-induced MMP-9 expression is
mediated through transcription and translation, a tran-
scription inhibitor Act.D and a translation inhibitor CHI
were used for these purposes. The data showed that the
pretreatment with either Act.D or CHI concentration-
dependently blocked TNF-α-induced MMP-9 expression
determined by gelatin zymography (Figure 1C), suggest-
ing that TNF-α-induced proMMP-9 expression occurs
at both transcriptional and translational levels. Addition-
ally, TNF-α-induced MMP-9 mRNA expression was
inhibited by Act.D, but not CHI, revealed by real-time
PCR (Figure 1D). These results indicated that TNF-α in-
duces MMP-9 expression via both transcription and
translation levels in MC3T3-E1 cells.
Involvement of TNFR1-dependent pathway in TNF-α-
induced MMP-9 expression
TNF receptor l (TNFR1) and TNF receptor-associated
factor 2 (TRAF2) generate distinct signals by TNF-α for
the induction of differently biological responses in many
cell types. Recent evidences suggest that MMP-9 expres-
sion was markedly suppressed in TNFR1 KO mice as
compared to wild-type mice [37]. Previously, Lee et al.
have demonstrated that TNF-α triggered the association
between TNFR1 and TRAF2 to induce the MMP-9 ex-
pression in A549 cells [38]. In addition, TNFR1 may as-
sociate with kinases such as c-Src to engage signaling
pathways, activate transcription factors, and modulate
gene expression in various cell types [39]. Therefore, to
investigate whether TNF-α induces MMP-9 expression
via TNFR1, a neutralizing TNFR antibody was used. As
shown in Figure 2A, the pretreatment with the TNFR
antibody attenuated TNF-α-induced MMP-9 expression
in a concentration-dependent manner. Moreover, to
demonstrate whether TNFR1-relative proteins are in-
volved in this response, the cell lysates were immuno-
precipitated using an anti-TNFR1 antibody and analyzed
by Western blot. As shown in Figure 2B, TNF-α stimu-
lated association of TNFR1, TRAF2, and c-Src in a
time-dependent manner. There was a significant in-
crease of TRAF2 and c-Src within 3–5 min during the
period of observation. Furthermore, the pretreatment
with a c-Src inhibitor PP1 attenuated TNF-α-induced
MMP-9 expression in a concentration-dependent man-
ner (Figure 2C), confirming that TNF-α-induced MMP-9
expression is mediated through c-Src. Similarly, pretreat-
ment with PP1 also inhibited TNF-α-induced MMP-9
mRNA expression (Figure 2D). Moreover, we investigated
Figure 1 TNF-α induces MMP-9 expression through transcription and translation levels. (A) MC3T3-E1 cells were incubated with various
concentrations of TNF-α for the indicated time intervals. The conditioned media were collected and analyzed by gelatin zymography. The
proteolytic activities of MMP-9 and MMP-2 were manifested as horizontal white bands on a blue background, and the expression of MMP-2
served as an internal control. (B) Cells were treated with TNF-α (15 ng/ml) for various time intervals. The total RNA were collected and analyzed
by RT-PCR and real-time PCR. (C) Growth-arrested cells were pretreated with various concentrations of either Act. D or CHI for 1 h and then
incubated with TNF-α (15 ng/ml) for 24 h. The conditioned media were collected and assayed by gelatin zymography. The cell lysates were
analyzed by Western blot to determine the expression of GAPDH as an internal control. (D) Cells were pretreated with Act.D (1 nM) or CHI
(100 nM) for 1 h and then incubated with TNF-α (15 ng/ml) for 6 h. The isolated RNA samples were analyzed for the level of MMP-9 mRNA by
real-time PCR. Data are expressed as mean±SEM of three independent experiments. *P < 0.05, #P <0.01, as compared to the cells treated with
vehicle (A,B) and TNF-α alone (C,D).
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phorylation was determined by Western blot using anti-
phospho-c-Src antibody and transfection with siRNA forTRAF2. As shown in Figure 2E and G, TNF-α time-
dependently stimulated c-Src phosphorylation with a
significant increase within 10 min and a maximal
Figure 2 (See legend on next page.)
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Figure 2 TNF-α induces MMP-9 expression via TNFR1-dependent c-Src cascade. (A) Cells were pretreated with various concentrations of
TNF-α receptor antibody (TNFR Ab) for 1 h and then incubated with TNF-α (15 ng/ml) for 24 h. (B) MC3T3-E1 cells were incubated with TNF-α
(15 ng/ml) for the indicated time intervals, and the protein-protein interaction was determined by immunoprecipitation (IP) and Western blot
using the antibodies as indicated. (C,D) Cells were treated with TNF-α (15 ng/ml) for (C) 24 h or (D) 6 h in the absence or presence of PP1.
(D) The isolated RNA samples were analyzed for the levels of MMP-9 mRNA by real-time PCR. Data are expressed as mean±SEM of three inde-
pendent experiments. *P < 0.05; #P < 0.01, as compared to the cells incubated with TNF-α alone. (E,G) Cells were pretreated with or without PP1
(30 μM) for 1 h or transfected with TRAF2 siRNA and then stimulated with TNF-α for the indicated time intervals. Phosphorylation of c-Src was
determined by Western blot using an anti-phospho-c-Src antibody. (F,G) Cells were transfected with c-Src siRNA or TRAF2 siRNA for 24 h and
then incubated with TNF-α (15 ng/ml) for 24 h. (A,C,F,G) MMP-9 expression was determined as described in Figure 1. The cell lysates were
determined by Western blot using an anti-c-Src, anti-TRAF2 or anti-GAPDH antibody.
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PP1 (30 μM) and siRNA for TRAF2 significantly at-
tenuated c-Src phosphorylation in response to TNF-α
during the period of observation. To further confirm
the role of c-Src or TRAF2 in TNF-α-induced MMP-9
expression, cells were transfected with c-Src or
TRAF2 siRNA and then incubated with TNF-α for
24 h. Transfection with c-Src or TRAF2 siRNA down-
regulated the total c-Src or TRAF2 protein expression
and attenuated TNF-α-induced MMP-9 expression
(Figure 2F and H). These results suggested that TNF-
α-induced MMP-9 expression is mediated through
TNFR1-dependent TRAF2 linking to c-Src cascade in
MC3T3-E1 cells.TNF-α induces MMP-9 expression via ERK1/2
phosphorylation
MAPKs, including ERK1/2, p38 MAPK, and JNK1/2,
can regulate expression of several genes through ac-
tivation of downstream kinases or nuclear proteins.
Previous study has demonstrated that TNF-α induces
MMP-9 expression via p42/p44 MAPK and JNK1/2
in A549 cells [40]. Here, to determine whether ERK1/2
activation is involved in TNF-α-induced MMP-9 expres-
sion in MC3T3-E1 cells, a pharmacological inhibitor of
MEK1/2 (U0126) was used. Pretreatment with U0126 at-
tenuated TNF-α-induced MMP-9 protein expression in a
concentration-dependent manner (Figure 3A) and MMP-
9 mRNA expression (Figure 3B), suggesting that MEK1/
2-ERK1/2 is involved in TNF-α-induced MMP-9 expres-
sion. To further determine whether phosphorylation of
ERK1/2 is necessary for TNF-α-induced MMP-9 expres-
sion, activation of ERK1/2 was assayed by Western blot
using an antibody specific for the phosphorylated, active
forms of ERK1/2. As shown in Figure 3C, TNF-α time-
dependently stimulated ERK1/2 phosphorylation with a
significant increase within 10 min and a maximal re-
sponse within 15 min in MC3T3-E1 cells. Pretreatment
with U0126 (3 μM) significantly attenuated TNF-α-
induced ERK1/2 phosphorylation during the period of
observation. These results suggested a link betweenactivation of the ERK1/2 pathway and up-regulation of
MMP-9 induced by TNF-α in MC3T3-E1 cells. To fur-
ther confirm the role of ERK1/2 in TNF-α-induced MMP-
9 expression, cells were transfected with ERK2 siRNA and
then incubated with TNF-α for 24 h. Transfection with
ERK2 siRNA down-regulated the total ERK2 protein
expression and attenuated TNF-α-induced MMP-9 ex-
pression (Figure 3D). These data suggested that TNF-α-
induced MMP-9 expression is mediated through a MEK1/
2-ERK1/2 pathway in MC3T3-E1 cells.TNF-α-induced MMP-9 expression via p38 MAPK
phosphorylation
To determine whether p38 MAPK is involved in TNF-α-
induced MMP-9 expression, a p38 MAPK inhibitor
(SB202190) was used. As shown in Figures 4A and B, the
pretreatment with SB202190 significantly attenuated
TNF-α-induced MMP-9 expression in a concentration-
dependent manner and mRNA expression revealed by
gelatin zymography and real-time PCR, respectively. To
further determine whether TNF-α stimulates p38 MAPK
activation, the phosphorylation of p38 MAPK was
assayed by Western blot using an antibody specific for
the phosphorylated, active form of p38 MAPK. As shown
in Figure 4C, TNF-α time-dependently stimulated phos-
phorylation of p38 MAPK in MC3T3-E1 cells. A max-
imal response was obtained within 10 min and declined
to the basal level within 30 min. Moreover, pretreatment
with SB202190 (particularly 30 μM) attenuated TNF-α-
stimulated p38 MAPK phosphorylation during the period
of observation. These results suggested a link between
phosphorylation of p38 MAPK and up-regulation of
MMP-9 induced by TNF-α in MC3T3-E1 cells. To fur-
ther ensure the involvement of p38 MAPK in TNF-α-
induced MMP-9 expression, cells were transfected with
p38 MAPK siRNA. The results showed that transfection
with p38 MAPK siRNA down-regulated the total p38
protein expression and attenuated TNF-α-induced
MMP-9 expression (Figure 4D). These data suggested
that TNF-α-induced MMP-9 expression is mediated
through a p38 MAPK pathway in MC3T3-E1 cells.
Figure 3 TNF-α induces MMP-9 expression via ERK1/2 phosphorylation. (A) Cells were pretreated with U0126 for 1 h and then incubated
with TNF-α (15 ng/ml) for 24 h. (B) Cells were pretreated with U0126 (3 μM) for 1 h and then incubated with TNF-α (15 ng/ml) for 6 h. The
isolated RNA samples were analyzed for the levels of MMP-9 mRNA by real-time PCR. (C) Cells were pretreated with or without U0126 (3 μM) for
1 h and then stimulated with TNF-α for the indicated time intervals. Phosphorylation of ERK1/2 was determined by Western blot using an
anti-phospho-ERK1/2 antibody. Data are expressed as mean±SEM of three independent experiments. #P < 0.01, as compare with the cells treated
with TNF-α alone. (D) Cells were transfected with ERK2 siRNA for 24 h and then incubated with TNF-α (15 ng/ml) for 24 h. (A,D) MMP-9 expression
was determined as described in Figure 1. The cell lysates were determined by Western blot using an anti-ERK2 or anti-GAPDH antibody.
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phosphorylation
In addition, to determine whether the activation of JNK1/
2 is also involved in TNF-α-induced MMP-9 expression, a
pharmacological inhibitor of JNK1/2 SP600125 was used.
As shown in Figures 5A and B, the pretreatment with
SP600125 attenuated TNF-α-induced MMP-9 expression
in a concentration-dependent manner and mRNA expres-
sion, revealed by zymography and real-time PCR. We
further investigated whether JNK1/2 phosphorylation
participates in TNF-α-induced MMP-9 expression in
MC3T3-E1 cells, activation of JNK1/2 was assayed by
Western blotting using an antibody specific for the phos-
phorylated, active forms of JNK1/2. We found that TNF-α
time-dependently stimulated JNK1/2 phosphorylation
with a significant increase within 10 min and a maximal
response within 60 min in MC3T3-E1 cells (Figure 5C),which was attenuated by the pretreatment with SP600125
during the period of observation. Moreover, we confirmd
the role of JNK1/2 in TNF-α-induced MMP-9 expression,
cells were transfected with a JNK2 siRNA. The data
showed that transfection with JNK2 siRNA down-
regulated the total JNK2 protein expression and attenu-
ated TNF-α-induced MMP-9 expression (Figure 5D).
These data suggested that TNF-α-induced MMP-9
expression is mediated through a JNK1/2 pathway in
MC3T3-E1 cells.
NF-κB is required for TNF-α-induced MMP-9 expression
Inflammatory responses following stimulation by TNF-α
are highly dependent on activation of the transcription fac-
tor NF-κB. Moreover, NF-κB is one of the major mediators
of the intracellular functions of TNF-α. Therefore, we in-
vestigated whether the involvement of NF-κB activation in
Figure 4 Involvement of p38 MAPK phosphorylation in TNF-α-induced MMP-9 expression. (A) Cells were pretreated with SB202190 for 1 h
and then incubated with TNF-α (15 ng/ml) for 24 h. (B) Cells were pretreated with SB202190 (30 μM) for 1 h and then incubated with TNF-α
(15 ng/ml) for 6 h. The isolated RNA samples were analyzed for the levels of MMP-9 mRNA by real-time PCR. Data are expressed as mean±SEM of
three independent experiments. *P < 0.05; #P < 0.01, as compare to the cells treated with TNF-α alone. (C) Cells were pretreated with or without
SB202190 (30 μM) for 1 h and then stimulated with TNF-α for the indicated time intervals. Phosphorylation of p38 MAPK was determined by
Western blot using an anti-phospho-p38 MAPK antibody. (D) Cells were transfected with p38 siRNA for 24 h and then incubated with TNF-α
(15 ng/ml) for 24 h. (A,D) MMP-9 expression was determined as described in Figure 1. The cell lysates were determined by Western blot using an
anti-p38 MAPK or anti-GAPDH antibody.
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NF-κB pharmacological inhibitor Bay11-7082 was used. As
shown in Figure 6A and B, the pretreatment with Bay11-
7082 caused an attenuation of TNF-α-induced MMP-9
protein in a concentration-dependent manner and mRNA
expression, revealed by zymography and real-time PCR, re-
spectively. We further determined whether TNF-α induces
MMP-9 expression through activation of an NF-κB up-
stream molecule IKKα/β and p65 NF-κB phosphorylation,
the phosphorylation of IKKα/β and p65 was assayed by
Western blotting using an antibody specific for the
phosphorylated, active forms of IKKα/β and p65, re-
spectively. As shown in Figure 6C (left panel), TNF-α
time-dependently stimulated phosphorylation of IKKα/
β and p65 in MC3T3-E1 cells.A significant response was obtained within 5–15 min
and declined to the basal level within 30 min. To investi-
gate whether TNF-α stimulates translocation of p65 NF-
κB, the cytosolic and nuclear fractions were used to de-
termine the p65 translocation by Western blotting using
an anti-p65 antibody. The data showed that TNF-α
time-dependently induced translocation of the p65
subunit of NF-κB into nucleus with a significant
increase within 15–30 min (Figure 6C, right panel).
Pretreatment with Bay11-7082 (10 μM) attenuated
TNF-α-stimulated p65 NF-κB translocation revealed
by Western blotting and immunofluorescence staining
analyses (Figure 6D), suggesting that NF-κB is essential
for TNF-α-induced MMP-9 expression in MC3T3-E1
cells. Moreover, to determine whether TNF-α stimulates
Figure 5 TNF-α induces MMP-9 expression via JNK1/2 phosphorylation. (A) Cells were pretreated with SP600125 for 1 h and then incubated
with TNF-α (15 ng/ml) for 24 h. (B) Cells were pretreated with SP600125 (3 μM) for 1 h and then incubated with TNF-α (15 ng/ml) for 6 h. The
isolated RNA samples were analyzed for the levels of MMP-9 mRNA by real-time PCR. (C) Cells were pretreated without or with SP600125 for 1 h
and then incubated with TNF-α (15 ng/ml) for various time intervals. The cell lysates were analyzed by Western blot using an anti-phospho-JNK1/
2 antibody or anti-GAPDH (as an internal control) antibody. Data are expressed as mean±SEM of three independent experiments. #P < 0.01, as
compare to the cells treated with TNF-α alone. *P < 0.05, as compare to the cells treated with TNF-α alone (A) or vehicle (C). (D) Cells were
transfected with JNK2 siRNA for 24 h and then incubated with TNF-α (15 ng/ml) for 24 h. (A,D) MMP-9 expression was determined as described
in Figure 1. The cell lysates were determined by Western blot using an anti-JNK2 or anti-GAPDH antibody.
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construct was used. As shown in Figure 6E, TNF-α stim-
ulated a time-dependent NF-κB transcriptional activity
with a maximal response by 4 h. Pretreatment with
Bay11-7082 significantly inhibited TNF-α-induced NF-
κB transcriptional activity. These results demonstrated
that NF-κB is required for TNF-α-induced MMP-9 ex-
pression in MC3T3-E1 cells.
TNF-α stimulates two independent pathways: c-Src-
dependent MAPKs and NF-κB-dependent cascades in
MC3T3-E1 cells
According to the above data, we have demonstrated that
TNF-α induced MMP-9 expression via activation of c-
Src, ERK1/2, p38 MAPK, JNK1/2, and NF-κB inMC3T3-E1 cells. It would be important to determine
the relationship among these molecules, including c-Src,
MAPKs, and NF-κB in the responses. Cells were pre-
treated with the inhibitor of c-Src (PP1), MEK1/2
(U0126), p38 MAPK (SB202190), or JNK1/2 (SP600125)
for 1 h and then stimulated with TNF-α for the indicated
time intervals. Phosphorylation of ERK1/2, p38 MAPK,
JNK1/2, IKKα/β and p65 was assayed by Western blot-
ting. As shown in Figure 7A, TNF-α-stimulated phos-
phorylation of ERK1/2, p38 MAPK, and JNK1/2, but not
IKKα/β and p65 was significantly attenuated by the pre-
treatment with PP1 during the period of observation.
Moreover, PP1 has inhibitory effects on not only c-Src
but also other Src family kinases. Therefore, MC3T3-E1
cells were transfected with c-Src siRNA to confirm
Figure 6 (See legend on next page.)
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Figure 6 NF-κB is required for TNF-α-induced MMP-9 expression. (A) Cells were pretreated with Bay11-7082 for 1 h and then incubated with
TNF-α (15 ng/ml) for 24 h. MMP-9 expression was determined as described in Figure 1. (B) Cells were pretreated with Bay11-7082 (10 μM) for 1 h
and then incubated with TNF-α (15 ng/ml) for 6 h. The isolated RNA samples were analyzed for the levels of MMP-9 mRNA by real-time PCR. (C)
Cells were incubated with TNF-α (15 ng/ml) for the indicated time intervals. The cell lysates were analyzed by Western blot using an anti-
phospho-IKKα/β, anti-phospho-p65, or anti-β-actin antibody (left part). The cytosolic and nuclear fractions were analyzed by Western blot using
an anti-NF-κB (p65), anti-Lamin A, and anti-GAPDH antibody (right part). (D) Cells were pretreated without or with Bay11-7082 (10 μM) for 1 h
and then stimulated with TNF-α (15 ng/ml) for 15 min. The nuclear fraction was analyzed by Western blot using an anti-NF-κB (p65) and
anti-Lamin A antibody. The translocation of p65 NF-κB was also observed by immunofluorescence staining (middle part) and the histogram of
p65 translocation (lower part). (E) Cells were transiently transfected with NF-κB-Luc construct and then incubated with TNF-α (15 ng/ml) for the
indicated time intervals in the absence or presence of Bay11-7082 (10 μM). The cell lysates were collected and determined the luciferase activity.
Data are expressed as mean±SEM of three independent experiments. #P < 0.01, as compare to the cells treated with TNF-α alone. *P < 0.05, as
compare to the cells treated with TNF-α (A,B,E) or vehicle alone (E).
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ited by c-Src knockdown. The data were correlated with
Figure 7A, TNF-α-stimulated phosphorylation of ERK1/
2, p38 MAPK, and JNK1/2, but not IKKα/β and p65 was
significantly attenuated by transfection with siRNA of c-
Src during the period of observation (Figure 7B). The
data demonstrated that TNF-α-stimulated phosphoryl-
ation of ERK1/2, p38 MAPK, and JNK1/2 is dependent
on c-Src activation. TNF-α-stimulated p65 NF-κB activa-
tion was independent of c-Src. Moreover, we found that
TNF-α-stimulated p65 phosphorylation and transloca-
tion was not significantly inhibited by the pretreatment
with U0126, SB202190, or SP600125 determined by
Western blotting during the period of observation
(Figure 7C) and immunofluorescence staining of p65 NF-
κB (Figure 7D). Subsequently, we also demonstrated that
TNF-α-stimulated NF-κB transcriptional activity is inde-
pendent of these MAPKs, revealed by NF-κB-luciferase
reporter assay (Figure 7E). These data demonstrated that
TNF-α induced MMP-9 expression via two independent
pathways, including c-Src-dependent MAPKs and c-Src-
independent IKK/NF-κB cascades in MC3T3-E1 cells.
The NF-κB element is important for TNF-α-induced
MMP-9 gene promoter activation
Several studies have shown that up-regulation of MMP-9
mRNA is mediated through an NF-κB-dependent pathway
[35]. MMP-9 promoter also contains NF-κB binding sites
[41]. To determine whether NF-κB element is essential for
TNF-α-induced MMP-9 gene regulation, the MMP-9 pro-
moter was constructed into a pGL3-Basic vector containing
a luciferase reporter system (as illustrated in Figure 8A,
upper part; pGL-MMP-9-Luc), which contains several pu-
tative recognition elements for a variety of transcriptional
factors such as NF-κB. Next, to determine the effect of
TNF-α on the MMP-9 promoter activity, cells were trans-
fected with a pGL-MMP-9-Luc construct and then incu-
bated with TNF-α for the indicated time intervals. As
shown in Figure 8A (lower panel), TNF-α increased the
MMP-9 promoter activity in a time-dependent manner. A
maximal response was obtained within 10 h. The increasingof MMP-9 promoter activity stimulated by TNF-α was sig-
nificantly inhibited by pretreatment with the TNFR anti-
body or the inhibitor of c-Src (PP1), MEK1/2 (U0126), p38
MAPK (SB202190), JNK1/2 (SP600125), or NF-κB (Bay11-
7082) (Figure 8B). To further ensure that NF-κB indeed
mediated TNF-α-induced MMP-9 promoter activity
through binding to NF-κB element on the MMP-9 pro-
moter region, a wild-type (WT) MMP-9 promoter mu-
tated by a single-point mutation of the NF-κB binding site
(mt-κB) was constructed (as indicated in Figure 8C, upper
part), TNF-α-stimulated MMP-9 promoter activity was
significantly blocked in MC3T3-E1 cells transfected with a
mt-κB-MMP-9 reporter construct (Figure 8C, lower part),
indicating that NF-κB binding element was required for
TNF-α-induced MMP-9 promoter activity. These results
demonstrated that TNF-α-induced MMP-9 promoter ac-
tivity is mediated through an NF-κB binding domain of
the MMP-9 promoter region in MC3T3-E1 cells.
TNF-α-induced MMP-9 expression contributes to
enhancing soluble ICAM-1 production
Previous report has shown that TNF-α induces membrane
and soluble forms of ICAM-1 release by MMP-9 activity in
human osteoblast-like cells [29]. Thus, we determined
whether up-regulation of MMP-9 by TNF-α may contrib-
ute to a MMP-dependent release of sICAM-1, a broad
spectrum MMP inhibitor GM6001, and an MMP-2/9
selective inhibitor MMP-2/9i, were used. As shown in
Figure 8D (upper panel), TNF-α-enhanced sICAM-1 re-
lease in the conditioned media was attenuated by the pre-
treatment with GM6001 (10 μM) or MMP-2/9i (10 μM),
suggesting that MMP-9 participates in TNF-α-induced
sICAM-1 release. Similarly, sICAM-1 release was also de-
tected by using a high sensitive sICAM-1 ELISA kit. The
data showed that TNF-α significantly enhanced sICAM-1
release within 36 h which was significantly inhibited by the
pretreatment with MMP-2/9i (10 μM), PP1 (10 μM),
U0126 (10 μM), SB202190 (10 μM), SP600125 (10 μM), or
Bay11-7082 (10 μM), in MC3T3-E1 cells (Figure 8D, lower
part). Furthermore, we found that there was no effect on
the ICAM-1 protein expression induced by TNF-α in the
Figure 7 TNF-α stimulates c-Src-dependent MAPKs and NF-κB-dependent cascades in MC3T3-E1 cells. MC3T3-E1 cells were pretreated
with 3 μM PP1 (A) transfected with c-Src siRNA (B) or pretreated with (C) U0126 (3 μM), SB202190 (3 μM), or SP600125 (3 μM) for 1 h, and then
stimulated with TNF-α (15 ng/ml) for the indicated time intervals. The cell lysates were analyzed by Western blot using an anti-phospho-ERK1/2,
anti-phospho-p38 MAPK, anti-phospho-JNK1/2, anti-phospho-IKKα/β, anti-phospho-p65, or anti-GAPDH (as a control) antibody. (D) Cells were
pretreated with U0126 (3 μM), SB202190 (3 μM), SP600125 (3 μM), or TNF-α receptor 1 neutralized antibody (TNFR nAb) for 1 h and then
stimulated with TNF-α (15 ng/ml) for 15 min. The translocation of p65 NF-κB was observed by immunofluorescence staining. (E) Cells were
transfected with NF-κB-Luc construct, pretreated with U0126 (3 μM), SB202190 (3 μM), or SP600125 (3 μM) for 1 h, and then incubated with
TNF-α (15 ng/ml) for 4 h. The cell lysates were collected and determined NF-κB-Luc activity. Similar results were obtained in three
independent experiments.
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(Figure 8E). Taken together, these data confirmed that up-
regulation of MMP-9 is associated with the release of
sICAM-1 on MC3T3-E1 cells challenged with TNF-α.
Discussion
MMP-9 is highly expressed in osteoclasts and plays
an important role in degradation of ECM. Given the
role of osteoblasts in building the bone, it is some-
what counter-intuitive that they also express many
matrix degrading MMPs including MMP-2, MMP-3,
MMP-8, MMP-9, MMP-13, and MMP-14 [42]. It is
generally accepted that locally increased levels of
MMPs have been found in several osteoarticular dis-
eases [6]. Of considerable importance in osteoarticu-
lar diseases, MMP-2 and MMP-9 can degrade anddenature type I and V collagen. Most studies support
the notion that TNF-α induces the production of
MMP-9 in different cell types [20,38]. Several lines
of evidence suggest that TNF-α treatment of cul-
tured bone explants or cell cultures of mineralizing
osteoblasts increased bone resorption and inhibited bone
formation [43]. In response to inflammatory processes of
bone microenvironment, MMP-9 synthesis and secretion
were significantly induced by TNF-α in mesenchymal
stem cells-derived osteoprogenitor, precursor of osteo-
blasts [13]. In this study, we established specific mecha-
nisms by which TNF-α promotes MMP-9 expression in
osteoblasts-like MC3T3-E1 cells. Based on these findings,
Figure 8F depicts a model for the TNFR1-mediated acti-
vation of c-Src-dependent MAPKs (i.e. ERK1/2, p38
MAPK, and JNK1/2) and c-Src-independent IKK-NF-κB
Figure 8 (See legend on next page.)
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Figure 8 TNF-α-induced MMP-9 expression is mediated through the NF-κB element in MMP-9 promoter leading to soluble ICAM-1
release. (A) Cells were transiently transfected with a wild-type MMP-9 promoter-luciferase reporter construct (WT-MMP9), and then incubated
with TNF-α for the indicated time intervals. (B) The WT-MMP9 transfected cells were pretreated with anti-TNFR1 neutralizing antibody (TNFR-Ab,
10 μg/ml), PP1 (3 μM), U0126 (3 μM), SB202190 (3 μM), SP600125 (3 μM), and Bay11-7082 (10 μM) for 1 h and then incubated with 15 ng/ml
TNF-α for 6 h. (C) Cells were transfected with WT-MMP9 or mt-κB-MMP9 for 24 h and then incubated with TNF-α (15 ng/ml) for 6 h. The cell
lysates were collected and determined the luciferase activity. (D,E) Cells were pretreated with GM6001 or MMP2/9i for 1 h and then incubated
with TNF-α (15 ng/ml) for 24 h. (D, upper panel) Conditioned media were collected and analyzed by gelatin zymography to determine the
MMP-9 expression. The conditioned media were analyzed by trichloroacetic acid-protein precipitation and Western blot using an anti-sICAM-1
antibody. (E) The cell lysates were analyzed by Western blot to determine the expression of ICAM-1. (D, lower panel) Cells were pretreated with
MMP-2/9i (10 μM), PP1 (10 μM), U0126 (10 μM), SB202190 (10 μM), SP600125 (10 μM), or Bay11-7082 (10 μM) for 1 h and then incubated with
TNF-α (15 ng/ml) for the indicated time intervals. The levels of sICAM-1 were determined in conditioned media using an sICAM-1 ELISA kit. Data
are expressed as mean±SEM of three independent experiments. #P < 0.01, as compare to the cells exposed to vehicle (A,D) or TNF-α alone (B-D).
(F) Schematic representation of signaling pathways involved in TNF-α-induced MMP-9 expression and sICAM-1 release in MC3T3-E1 cells. TNF-α
stimulates two independent pathways through TNFR1/TRAF2 activates both c-Src-dependent MAPKs and c-Src-independent IKK/NF-κB pathways.
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expression and s-ICAM-1 release from MC3T3-E1 cells.
Several reports have indicated that most known re-
sponses to TNF-α are triggered by binding to one of
two distinct receptors, TNFRl and TNFR2, which are
differentially regulated on various cell types in nor-
mal and diseased tissues. In osteoblasts, TNF-α stim-
ulates osteoblast differentiation through its TNFR1
receptor [44]. Recent studies have further demon-
strated that TNFR1 signal transduction is mediated
through the assembly of kinases, adaptors, and scaf-
folding proteins which also interacts with TRAF2
and IKK leading to activation of NF-κB [45]. In
addition, several reports suggest that Src tyrosine kinases
promote inflammatory processes under various patho-
logic conditions. For example, T cell protein tyrosine
phosphatase interacted with TRAF2 and inactivated c-Src
tyrosine kinases to selectively suppress TNF-α-induced
MAPK signaling and modulate inflammatory responses
[46]. However, little was known about the mechanisms of
TNF-α-induced MMP-9 expression mediated through
TNFR1-TRAF2-c-Src-dependent pathway in osteoblasts.
Here, we hypothesized that TRAF2 and c-Src are signal
transducers of TNFR1 in osteoblasts. This note was con-
firmed by the results indicating that TNF-α-induced
MMP-9 expression was significantly blocked by TNFR
antibody and c-Src inhibitor. Moreover, we used immu-
noprecipitation to determine the interaction among
TNFR1, TRAF2, and c-Src to confirm that TNF-α
induced TNFR1, TRAF2 and c-Src association. TNF-α
has further been shown to stimulate the phosphoryl-
ation of c-Src which was also attenuated by c-Src inhibi-
tor PP1 and siRNA for TRAF2. Our data were first
identified that TNF-α up-regulates the interaction be-
tween TNFR1, TRAF2, and c-Src components, leading
to MMP-9 expression in osteoblasts. These results sug-
gested that TNF-α induces MMP-9 expression via
TNFR1/TRAF2-mediated activation of c-Src in MC3T3-
E1 cells.Several groups of investigators have reported that
TNF-α released during acute and chronic diseases acti-
vates multiple intracellular signaling cascades including
the MAPKs and NF-κB signaling pathways in various
cell types. Previous reports have shown that aggregation
of TNFR1/TRAF2 protein complex transducer activates
downstream IKKα/β-NF-κB cascade and JNK1/2 and
p38 MAPK in skeletal pathologies [43]. TNF-α, a potent
pro-inflammatory cytokine, has been reported to activate
downstream protein kinases cascade such as MAPKs in
various cells types [47]. For example, phosphorylation of
p42/p44 MAPK and JNK1/2, and transactivation of NF-
κB are essential for TNF-α-induced MMP-9 gene ex-
pression in A549 cells [40]. However, the activated
TNFR1/TRAF2 stimulates MAPKs or NF-κB signaling
pathway leading to TNF-α-induced MMP-9 expression
in osteoblasts remains unclear. In this study, we found
that TNF-α-stimulated ERK1/2, p38 MAPK, and JNK1/2
phosphorylation in MC3T3-E1 cells, which were attenu-
ated by the pretreatment with PP1 or transfection with
c-Src siRNA, suggesting that TNF-α stimulates phos-
phorylation of these MAPKs via a c-Src-dependent man-
ner (Figure 7A and B). These data suggested that TNF-α
induces MMP-9 expression is mediated through c-Src-
dependent MAPKs pathway in MC3T3-E1 cells.
In addition, NF-κB is an inducible transcription factor
that plays a key role in the expression of inflammatory
response genes. NF-κB plays a pivotal role in bone re-
modeling cycle [48]. TNF-α binds its receptor to activate
several intracellular signaling pathways. Aggregation of a
protein complex including TRAF2 transduces the signal
along the IKK/I-κB pathway leading to phosphorylation
of IκB-α with liberation of the transcription factor NF-
κB for nuclear entry and regulation of gene transcription
[43]. In this study, our data showed that pretreatment
with PP1 or transfection with siRNA of c-Src, had no
significant inhibition on TNF-α-stimulated IKKα/β and
p65 phosphorylation, suggesting that TNF-α-stimulated
p65 phosphorylation is independent of c-Src (Figure 7A
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MEK1/2, p38 MAPK, or JNK1/2 had no effect on TNF-
α-stimulated p65 phosphorylation (Figure 7C), nuclear
translocation (Figure 7D), and transcriptional activity
(Figure 7E), suggesting that TNF-α-stimulated p65
NF-κB activation is independent of c-Src/MAPKs in
MC3T3-E1 cells. Moreover, our data showed that TNF-
α stimulated IKKα/β phosphorylation (Figure 6C),
suggesting that activation of IKKα/β may contribute to
NF-κB activation in MC3T3-E1 cells. For the regulation
of MMP-9 promoter, we also demonstrated that TNF-α-
stimulated activation of MMP-9-promoter-luciferase
activity was inhibited by pretreatment with TNFR1 anti-
body, PP1, U0126, SB202190, SP600125, or Bay11-7082
(Figure 8B). We further confirmed that NF-κB binding
site within MMP-9 promoter is important for TNF-α-
induced MMP-9 expression by transfection with a
MMP-9 promoter constructed with NF-κB binding site
mutation (Figure 8C), indicating that NF-κB binding do-
main is required for MMP-9 promoter activation by
TNF-α in MC3T3-E1 cells. These data suggested that
TNF-α-stimulated MMP-9 gene expression is mediated
through NF-κB-mediated up-regulating MMP-9 pro-
moter activity, and which involved TNFR1, c-Src-
dependent MAPKs (i.e. ERK1/2, p38 MAPK, and JNK1/
2) and c-Src-independent IKK/NF-κB pathways. MAPKs
are serine/threonine protein kinases, which contribute to
several cellular pathophysiological responses through
regulation of their downstream molecules including tran-
scription factors. Previous studies have indicated that TNF-
α induces MMP-9 expression via a MAPK-dependent acti-
vation of NF-κB or AP-1 in several cell types [37,39,49].
Here we demonstrated that TNF-α-induced MMP-9 ex-
pression is mediated through a MAPK-independent NF-κB
pathway. Next, we also suggested that TNF-α might induce
MMP-9 expression via a MAPK-dependent AP-1 pathway
in MC3T3-E1 cells. These results will be confirmed in the
future.
In bone metabolism, ICAM-1 importantly mediates cell-
cell adhesion of osteoblasts and osteoclast precursors,
thereby facilitating osteoclast differentiation and bone re-
sorption [25,50]. Osteoblasts regulate osteoclast recruit-
ment of bone resorption through RANKL and ICAM-1. In
bone diseases, blockage of the interaction between TNF-α
and sICAM-1 may inhibit not only inflammation in the
joints but also bone resorption by suppressing the
osteoblast-mediated formation of osteoclasts [24]. Treat-
ment of osteoblasts with the chemical inhibitor of MMP-9
activity, a proteolytic enzyme involved in ICAM-1 cleavage,
displayed a significant decrease of TNF-α-induced sICAM-
1 release [29]. Finally, we examined a functional conse-
quence of TNF-α-induced MMP-9 expression in mature
osteoblasts by sICAM-1 determination. In this study, we
demonstrated that TNF-α induces MMP-9 up-regulationthat promotes sICAM-1 release into the conditioned media
(Figure 8D), but no effect on the ICAM-1 protein level
(Figure 8E). Our results are consistent with previous report
indicating that TNF-α-increased MMP-9 activity may act
on mICAM-1 resulting in sICAM-1 release. These find-
ings concerning TNF-α-induced MMP-9 expression and
sICAM-1 release in MC3T3-E1 cells imply that TNF-α
might play a critical role in the development of bone in-
flammatory process.
Conclusions
Our study provides new insights into the mechanisms by
which TNFR1/TRAF2 activates both IKKα/β-NF-κB and
c-Src-ERK1/2, p38 MAPK, and JNK1/2 pathways may
be associated with MMP-9 expression in osteoblasts-like
MC3T3-E1 cells (Figure 8F). In addition, our findings indi-
cated that increased MMP-9 may contribute to mICAM-1
protein cleavage on the surface of ostoblasts leading to
sICAM-1 release. Targeting MMP-9 inhibition by pharma-
cological approaches could have clinical interventions in
the treatment of bone loss diseases, such as arthritis and
aseptic loosening. Moreover, the capacity of MMP-9 to se-
lectively prevent production of sICAM-1 may be useful for
the development of novel therapeutic approaches relevant
for the management of bone inflammation.
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